Cytokinetics (CYTK) announced the appointment of James Daly to its Board of Directors effective August 19, 2025. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors. Most recently, Daly served as the Chief Commercial Officer at Incyte Corporation (INCY)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ Aficamten Study: A Potential Breakthrough for Pediatric Heart Health
- Cytokinetics: Promising Outlook with Aficamten’s Regulatory Progress and Strong Financial Health
- Cytokinetics’ Earnings Call: Progress Amid Challenges
- Buy Rating for Cytokinetics Driven by Regulatory Reviews and Strategic Trials for Drug Afi
- Cytokinetics price target lowered to $77 from $80 at Citi